PMDA List of articles

ELIQUENT Japan > PMDA

2026.10.09

White,medical,pills,and,tablets,spilling,out,of,a,drug

Early Consideration on General Toxicity Evaluation of Monoclonal Antibodies in Japan

Introduction to General Toxicity Evaluation of Monoclonal Antibodies On May 13, 2026, the Pharmaceuticals and […]

2026.09.15

Medical,balancing,act.,a,group,of,medicine,pills,and,antibiotics

Japan Joins FDA’s Project Orbis to Accelerate Global Oncology Drug Approvals

Introduction to Project Orbis is an international regulatory collaboration program established by the FDA Onco […]

2026.08.17

Drug,prescription,for,treatment,medication.,pharmaceutical,medicament,,cure,in,container

Early Consideration on Safety Measures for Bioequivalence Studies in Healthy Volunteers in Generic Drug Development in Japan

Introduction to Safety Considerations for Bioequivalence Studies According to the notification issued by the P […]

2026.08.12

Medical,balancing,act.,a,group,of,medicine,pills,and,antibiotics

Early Consideration for the Revision of Japan’s Regulatory Guidelines on Prototype Vaccines for Pandemic Influenza Preparedness

Introduction to the Early Consideration On July 31, 2026, Japan’s Pharmaceuticals and Medical Devices Agency ( […]

2026.07.07

Colorful,of,tablets,and,capsules,pill,in,blister,packaging,arranged

What scientific rationale and supporting evidence are required to substantiate the classification of a genetic alteration as a driver mutation in the development of Anti-cancer Drugs ?

Introduction to PMDA’s Early Consideration on Driver Mutations According to the Early Consideration docu […]

2026.06.24

Drug,prescription,for,treatment,medication.,pharmaceutical,medicament,,cure,in,container

Early Consideration on Clinical Evaluation of Factor VIII and Factor IX Products for Pediatric Congenital Hemophilia in Japan

Introduction to Pediatric Hemophilia Indication Development in Japan According to the communication issued by […]

2026.06.08

Blue,and,white,capsules,pill,spilled,out,from,white,plastic

Considerations for Determining the Need for Comparative Efficacy Studies in Biosimilar Development in Japan

Introduction to PMDA’s Early Consideration on Comparative Efficacy Studies for Biosimilars According to the Ea […]

2026.05.13

Drug,prescription,for,treatment,medication.,pharmaceutical,medicament,,cure,in,container

Early Consideration on Clinical Development of In Vivo Diagnostic Drugs in Japan

Introduction to Early Consideration on In Vivo Diagnostic Drug DevelopmentAccording to the Early Consideration […]

2026.04.27

White,medical,pills,and,tablets,spilling,out,of,a,drug

Early Consideration on Food Effect Evaluation for Oral Drug Products in Japan

Introduction to Early Consideration on Food Effect Evaluation According to the notification issued by Pharmace […]

2026.04.13

Holograms,of,capsule;,charts,and,dna,helix,on,scientific,backdrop.

PMDA Early Consideration on Clinical Trials with a Limited Number of Subjects: Key Considerations for Drug Development in Japan

Introduction to Small Sample Clinical TrialsAccording to the notification issued by the Pharmaceuticals and Me […]

COMPANY

Company Name: Eliquent Japan, Inc.
Location: Shinjuku i-Land Tower 41F, 6-5-1 Nishi Shinjuku, Shinjuku-ku 163-1341 Tokyo, Japan
Representative Director, CEO: Shunsuke Iwano
Business Scope: Regulatory Consulting
 Phone:+81-3-6304-5570